Clinical Trial Update: The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety and efficacy of Daclatasvir and Asunaprevir in hepatitis C genotype 1b patients with chronic renal failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Myeong Jun Song | Conditions: Hepatitis C | Phase 4 | Status: COMPLETED